近日，药明康德（603259）子公司合全药业荣膺2023年“CDMO领军企业奖”，并获得“能力”（Capabilities）以及 “可靠性”（Reliability）两大核心奖项。这也是合全药业第九次荣膺“CDMO领军企业奖”。

(资料图片)

“CDMO Leadership Awards”由美国行业媒体Outsourced Pharma及Life Science Leader，与市场调研机构Industry Standard Research（ISR）共同颁发，旨在表彰在“能力” (Capabilities)、“可靠性”（Reliability）等方面表现突出的全球优质合作研发生产企业。2023年，评审组邀请欧美大中小型公司围绕23个关键指标，对全球72家合同生产服务商进行严格筛选与综合评审，涵盖全球范围内不同规模的制药和生物制药公司。合全药业凭借卓越表现，再次脱颖而出荣膺奖项，彰显了全球合作伙伴对合全药业一体化、端到端研发及生产服务能力的高度认可。

合全药业深耕CDMO领域20余年，目前在全球设有14个研发及生产基地，分别位于亚洲、北美及欧洲地区，全球员工已超过14,000名。仅2022年合全药业就为全球1,200多家各类生物医药企业提供赋能服务。凭借业界领先的一体化CMC赋能平台，以及符合国际标准的质量体系，合全药业2017年以来已成功支持合作伙伴的38款创新药获批，支持的新药在全球105个国家上市。

药明康德联席首席执行官、合全药业首席执行官陈民章博士表示：“我们很荣幸再次荣膺‘CDMO领军企业奖’，感谢合作伙伴对合全药业的高度认可及信任。合全药业始终致力于为全球合作伙伴提供高质量、可信赖、灵活的CRDMO服务，未来，我们将继续提升平台能力，助力加速创新药开发进程，为广大病患带来健康福音。”

关于合全药业

合全药业是药明康德子公司，在亚洲、北美及欧洲地区均设有研发及生产基地。合全药业服务于生命科学行业，拥有卓越的化学创新药研发和生产的能力和技术平台。作为全球新药合同研究、开发与生产领域（CRDMO）的领军企业，合全药业致力于为全球合作伙伴提供高效、灵活、高质量的一站式解决方案，以支持包括小分子、寡核苷酸、多肽及各种复杂化学偶联药物的研发与生产。更多信息，请访问公司网站：www.stapharma.com.cn WuXi STA Receives 2023 CDMO Leadership Award in Recognition of Capabilities and Reliabilities

WuXi STA, a global leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to share that it has been named a recipient of the 2023 CDMO Leadership Award for the ninth consecutive year. WuXi STA received recognition in two core categories: Capabilities and Reliabilities, which underscores the company’s ongoing commitment to supporting its global partners in new drug development.

For the 2023 CDMO Leadership Awards, Outsourced Pharma and Life Science Leader Magazine teamed up with Industry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey that captured input from decision makers, aiming to recognize the top CDMOs achieving outstanding performance. 72 contract manufacturers were assessed by 23 performance metrics in ISR"s annual Contract Manufacturing Quality Benchmarking survey, covering all sizes of companies from both Pharma and Biopharma industries.

With over two decades of dedication to the CDMO industry, WuXi STA has established a global R&D and manufacturing network of 14 sites across North America, Asia, and Europe with over 14,000 employees, serving more than 1,200 customers in 2022 alone. By leveraging its end-to-end integrated CRDMO platform and a global standard quality system, WuXi STA has supported the approval of 38 new drugs since 2017. The products manufactured by the company have been launched in 105 countries, helping millions of patients worldwide.

Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, commented, “We are honored to receive the 2023 CDMO Leadership Award again this year, and we are grateful to our partners for their recognition and trust. WuXi STA remains committed to delivering world-class CRDMO services to accelerate life-changing medicines to market for the benefit of patients around the world.”

About WuXi STA WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier contract development and manufacturing organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.

For more information, please visit: http://www.STApharma.com